Results 261 to 270 of about 304,306 (307)
Data were included from adolescents with moderate‐to‐severe AD treated with the JAK1 inhibitor abrocitinib (200 mg/100 mg) across JADE clinical trials. Improvements in skin clearance (per EASI‐75) and itch (per PP‐NRS4) were maintained for up to 112 weeks with both abrocitinib doses.
Amy S. Paller+13 more
wiley +1 more source
Rationalizing antibiotic prescribing for bacterial pneumonia in patients with reported penicillin allergy-a qualitative study. [PDF]
Lau XMN+5 more
europepmc +1 more source
Hospitalization due to pneumonia in Australia, England, and Wales: An ecological cross-sectional study. [PDF]
Samannodi M.
europepmc +1 more source
Transcriptomic Biomarkers Associated With Microbiological Etiology and Disease Severity in Childhood Pneumonia. [PDF]
Williams DJ+12 more
europepmc +1 more source
Severe Pulmonary Blastomycosis in a Young Adult: Probable Role of E-Cigarette Use in Immunosuppression. [PDF]
Gupta R+6 more
europepmc +1 more source
A multi-modal deep learning solution for precise pneumonia diagnosis: the PneumoFusion-Net model. [PDF]
Wang Y+8 more
europepmc +1 more source
Alcohol consumption has a J-shaped association with bacterial infection and death due to infection, a population-based cohort study. [PDF]
Stattin K+6 more
europepmc +1 more source